Condition
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Mrna1469
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 1 (2)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07919197Phase 1Not Yet RecruitingPrimary
A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of Age
NCT07737717Phase 1Active Not RecruitingPrimary
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Showing all 2 trials
Research Network
Common Treatments
- Mrna14692
Active Sponsors
- ModernaTX, Inc.2